普洛药业(000739) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥2,319,396,045.96, a decrease of 18.94% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2025 was ¥137,218,813.55, down 43.95% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2025 was ¥126,559,411.20, a decline of 44.66% compared to the previous year[5] - Total operating revenue decreased to ¥7,763,882,133.27 from ¥9,290,220,207.76, representing a decline of approximately 16.4% year-over-year[17] - Net profit for the period was ¥700,189,009.91, down from ¥869,388,123.84, indicating a decrease of approximately 19.5% year-over-year[17] - Total comprehensive income for the period was CNY 701,126,423.02, a decrease from CNY 872,959,496.18 in the previous period[19] - Basic and diluted earnings per share decreased to 0.6063 from 0.7466 year-over-year[19] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥774,024,106.67, representing a decrease of 33.60% year-on-year[9] - Net cash flow from operating activities was CNY 774,024,106.67, down from CNY 1,165,709,114.84 in the previous period, representing a decline of approximately 33.6%[21] - Cash inflow from operating activities totaled CNY 6,293,882,351.31, compared to CNY 8,083,217,866.85 in the previous period, indicating a decrease of about 22.1%[20] - Cash outflow from operating activities was CNY 5,519,858,244.64, down from CNY 6,917,508,752.01, reflecting a reduction of approximately 20.2%[21] - Net cash flow from investing activities was negative CNY 238,325,527.35, an improvement from negative CNY 364,538,076.21 in the previous period[21] - Cash inflow from investing activities increased to CNY 986,330,907.92 from CNY 243,447,417.35, a significant rise of approximately 304.5%[21] - Cash outflow from financing activities totaled CNY 2,190,685,623.07, compared to CNY 1,538,035,740.54 in the previous period, an increase of about 42.4%[21] - The ending cash and cash equivalents balance was CNY 2,698,713,039.68, slightly down from CNY 2,735,557,535.96 in the previous period[21] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥12,101,962,799.34, a decrease of 4.93% from the end of the previous year[5] - Current liabilities totaled ¥5,316,853,533.24, down from ¥5,742,629,852.13, a decrease of approximately 7.4% year-over-year[15] - Long-term borrowings increased to ¥173,096,972.22 from ¥70,053,541.67, representing a significant increase of approximately 147%[15] - The total equity attributable to shareholders decreased to ¥6,486,351,400.77 from ¥6,741,964,785.16, a decline of about 3.8% year-over-year[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 41,333[11] - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.57% of shares, totaling 330,941,729 shares[11] - The top 10 shareholders include Zhejiang Hengdian Import and Export Co., Ltd. with 13.51% and Zhejiang Hengrun Technology Co., Ltd. with 5.15%[11] - The company has repurchased a total of 10,030,000 shares, representing 0.87% of the total share capital[12] - The company has no preferred shareholders or related party transactions reported[12] - The total number of shareholders with voting rights restored is 0[11] - The company has not reported any changes in the lending of shares by major shareholders[12] Research and Development - Research and development expenses for the first nine months of 2025 amounted to ¥509,936,802.16, an increase of 9.15% compared to the same period last year[9] - Research and development expenses were ¥465,006,684.23, slightly down from ¥467,201,967.23, indicating a decrease of about 0.5% year-over-year[18] Financial Expenses - The company reported a financial expense of -¥28,944,097.36, compared to -¥14,045,020.76 in the previous period, reflecting an increase in financial costs[18] Other Financial Metrics - The weighted average return on equity for Q3 2025 was 2.11%, down 1.73% year-on-year[5] - The cash and cash equivalents net increase for the first nine months of 2025 was -¥30,731,520.38, a decline of 111.25% year-on-year[9] - Accounts receivable decreased to ¥1,622,265,537.75 from ¥1,764,198,282.30[13] - Inventory decreased to ¥1,601,631,107.87 from ¥1,860,088,103.67[13] - Deferred income tax liabilities decreased to ¥72,541,252.32 from ¥84,980,080.67, a reduction of approximately 14.7%[15] Audit Information - The company did not undergo an audit for the third quarter financial report[22]